A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aschaffenburg, Germany, Am Hasenkopf 1
- Klinikum Aschaffenburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient's written informed consent must be obtained prior to inclusion.
- Male or female outpatients or inpatients aged 40 to 80 years with an indication for complete colonoscopy.
- Willing to undergo a colonoscopy for diagnostic or surveillance purposes
- Patients with a known personal of familial risk of colon neoplasia, willing to undergo a screening colonoscopy
- Willing, able and competent to complete the entire procedure and to comply with study instructions.
- Females of childbearing potential must employ an adequate method of contraception.
Exclusion Criteria:
- History of gastric emptying disorders.
- History of ileus, toxic megacolon, gastrointestinal obstruction and colonic perforation.
- History of phenylketonuria.
- Known glucose-6-phosphate dehydrogenase deficiency.
- Known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/sodium ascorbate.
- History of colonic resection.
- Requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs).
- Presence of congestive heart failure (NYHA III + IV).
- Acute life-threatening cardiovascular disease.
- Documented history of severe renal insufficiency (creatinine clearance <30 ml/min).
- Other contraindication described in the summary of product characteristics (SmPC) of either preparation.
- Patient has a condition, clinically significant laboratory results, or is in a situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly.
- Application of any unlicensed medication within the previous 3 months or participation in any other research study in the last 3 months.
- Females who are pregnant, nursing or planning a pregnancy.
- Patients who, in the opinion of the investigator, may not be compliant with the study requirements.
- Previous participation in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: CitraFleet
Administration of CitraFleet
|
|
|
Experimental: MOVIPREP
Administration of MOVIPREP
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Polyp detection rate
Time Frame: At colonoscopy
|
Polyp detection rate defined as number of patients with at least one polyp or flat lesion as recorded by the endoscopist
|
At colonoscopy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adenoma Detection Rate (ADR)
Time Frame: At the Colonoscopy
|
ADR, (including flat lesions) defined as number of patients with at least one adenoma as recorded by the pathologist in relation to the total analysis population
|
At the Colonoscopy
|
|
ADR and PDR by location
Time Frame: at the colonoscopy
|
ADR and PDR by location:
|
at the colonoscopy
|
|
Cancer detection rate
Time Frame: at the colonoscopy
|
Cancer detection rate, defined as number of patients with at least one malignancy in relation to the total analysis population
|
at the colonoscopy
|
|
Flat lesion only detection rate
Time Frame: at the colonoscopy
|
Flat lesion only detection of the patients
|
at the colonoscopy
|
|
Advanced risk lesion detection rate
Time Frame: at the colonoscopy
|
Advanced risk lesion detection rate (lesions >1 cm, low grade and/or villous
|
at the colonoscopy
|
|
Colonoscopy completion rate
Time Frame: at the colonoscopy
|
The rate of colonoscopy completion
|
at the colonoscopy
|
|
Colon cleansing quality
Time Frame: at the colonoscopy
|
Colon cleansing quality as reported by the gastroenterologist, according to the Harefield Cleansing Scale©
|
at the colonoscopy
|
|
Acceptability and tolerability of medication using patient questionnaires
Time Frame: Throughout the study
|
The acceptability and tolerability of the study medication taken by the patients throughout the study using specified patient questionnaires
|
Throughout the study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wolfgang Fishbach, MD, Klinikum Aschaffenburg-Alzenau
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NOR-01/2011 (PDR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.